Green Park & Golf Ventures

Green Park & Golf Ventures invests in early-stage companies, particularly within the healthcare and biotech sectors. The firm targets businesses that demonstrate compassion, innovative ideas, and strong management teams. Investments typically range from $500,000 to $2,000,000, aimed at providing startup or growth capital. This investment strategy emphasizes companies operating in large markets with high barriers to entry, ensuring a competitive advantage.

The firm looks for founders who exhibit a strong vision and the ability to execute their ideas effectively. Green Park & Golf Ventures values innovative solutions that address significant medical challenges. Their investment thesis is centered on supporting companies that not only promise superior returns but also contribute positively to the healthcare landscape.

Green Park & Golf Ventures has a diverse portfolio of 15 companies, primarily focused on healthcare and biotech innovations. Notable portfolio companies include:

• Empirical Spine: Develops LimiFlex, a treatment alternative for spinal stenosis with instability.
• Esculon: Creates cardiothoracic post-operative medical equipment, including the Thoraguard surgical drainage system.
• Mission Bio: Focuses on single-cell biology to enhance precision medicine.
• MicroTransponder Inc: Offers the Vivistim® System for post-stroke upper limb impairment.
• Corvion: Works on a fully implantable left ventricular assist device (LVAD).
• RTRS Technologies: Innovates in dental implantology.
• Accuryn: Develops a monitoring system that enhances traditional Foley catheters.
• Channel Medsystems: Provides cryothermic treatment for heavy menstrual bleeding.
• Ataia Medical: Offers a communicator for patients undergoing respiratory therapies.
• Novascan: Focuses on improving cancer detection technologies.
• Noninvasix: Develops non-invasive precision oximetry solutions.
• Access Vascular: Creates venous access devices with patented biomaterials.
• Lantern Pharma: Utilizes AI for oncology drug discovery.
• Betaliq, Inc: Develops topical glaucoma treatments.
• Stingray Therapeutics: Works on innate immunity modulators.
• OncoNano Medicine: Develops products for cancer diagnosis and treatment.
• Barricade Therapeutics: Focuses on novel small molecules for cancer and neurology.

This portfolio reflects the firm's commitment to investing in innovative medical solutions that address critical healthcare needs.

Clay Heighten, M.D.: Founding Partner. Dr. Heighten brings extensive medical expertise and operational experience to the firm, having previously held leadership roles in various healthcare organizations.

Carl Soderstrom: Founding Partner. Soderstrom has a strong background in finance and venture capital, contributing to the firm's strategic investment decisions.

JR Garcia: Partner. Garcia focuses on sourcing and evaluating investment opportunities, leveraging his experience in the healthcare sector.

Dr. Lauren Tyra: Analyst. Dr. Tyra supports the investment team with market research and analysis, providing insights into emerging healthcare trends.

Daniel S. Parsley: Managing Partner, Houston. Parsley oversees the firm's Houston operations and plays a key role in expanding the firm's investment reach.

John Leader: Principal, Investment Operations. Leader manages the operational aspects of the firm's investments, ensuring efficient execution of strategies.

Claire England: Investment Partner. England focuses on building relationships with portfolio companies and supporting their growth initiatives.

Drew Soderstrom: Head of Investor Relations. Soderstrom manages communications with investors and stakeholders, ensuring transparency and engagement.

To pitch Green Park & Golf Ventures, founders should submit their proposals through the firm's contact page at gpgventures.com/contact. The pitch deck should include a comprehensive overview of the business model, market analysis, financial projections, and the team’s qualifications. Founders are encouraged to provide detailed information about their innovative solutions and how they address specific healthcare challenges.

Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.

As of March 2023, Green Park & Golf Ventures continues to expand its portfolio, focusing on innovative healthcare solutions. The firm has recently made investments in several early-stage medical startups, although specific details on these investments have not been disclosed.

In addition, the firm is actively seeking new opportunities within the healthcare sector, emphasizing its commitment to supporting companies that align with its investment philosophy. Green Park & Golf Ventures remains a key player in the Dallas venture capital scene, leveraging its expertise to drive growth in the medical technology space.